Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using ...

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

The findings were published Wednesday in the journal Nature. The new trial focused on patients with advanced, stage 3 or 4 ...

What is pelvic inflammatory disease (PID)? Pelvic inflammatory disease (PID) is an infection of a woman’s reproductive tract. It can affect the uterus, fallopian tubes, and the ovaries. PID can cause ...

It is the purpose of this report to describe a patient with extensive osteoblastic metastases, resulting from adenocarcinoma ... acute pancreatitis, renal disease, hypoproteinemia ...

now set as the standard front-line treatment for advanced renal cell carcinoma (RCC). However, the roles of VEGFR-TKIs and IOs in the neoadjuvant setting for locoregional/locally advanced RCC remain ...